David C. Evans to Join BOD at Cardinal Health

June 26, 2020

David C. Evans has been elected as an independent director, effective July 1. The news was announced by Cardinal Health.

David C. Evans brings decades of financial expertise and strong, diverse board experiences.

Most recently, David C. Evans served as interim Chief Financial Officer for Cardinal Health for approximately nine months. He previously held the role of Chief Financial Officer of Battelle Memorial Institute, one of the largest private, non-profit research organizations in the world. Prior to that, Mr. Evans served as Executive Vice President and Chief Financial Officer of The Scotts MiracleGro Company, the leading manufacturer and marketer of branded consumer lawn and garden products in North America.

Currently, Mr. Evans serves on the board of directors for Scotts MiracleGro and is a member of both the audit committee and the compensation and organization committee. He also serves on the board of directors for the Siegel Rare Neuroimmune Association and formerly served as a board member on the finance and audit committee for Ohio Health.

“We are pleased to welcome Dave as a director,” said Gregory Kenny, Chairman of the Board for Cardinal Health. “The Board has been impressed by both his operational instincts and his financial acumen. Dave sees both the big picture, as well as the value drivers, while never losing sight of our mission – being essential to care. We look forward to benefitting from his history as a strong and independent-minded leader as we continue to navigate this time of immense change and adapt our growth strategies for the future.”

Mr. Evans holds a Bachelor of Science in Business Administration degree in Accounting from The Ohio State University.

Hot this week

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."